Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplant
only.
Introduction
General radio-pharmacologic immunosuppression is the primary method used to decrease the immune rejection response of the host against allogeneic donor hematopoietic and organ transplant grafts. Development of more specific, cellular therapies designed to induce antigen (Ag)-specific tolerance would be widely applicable in many transplant settings. Studies have begun to investigate potential avenues for novel cellular-based therapies by producing tolerance using immature dendritic cells (DCs) alone 1, 2 , as well as DCs genetically modified to express a number of immunoregulatory genes, including IL-10 3 , TGF-4 , CTLA4-Ig 4 and Fas ligand (FasL) 5, 6 . These approaches have been shown to confer tolerance in certain defined experimental settings. The Fas pathway offers an intriguing opportunity to manipulate the anti-donor immune response in the BMT setting, since allograft rejection is mediated primarily by activated host anti-donor T cells, and since activated T cells generally express high levels of the Fas receptor and are susceptible to Fas-mediated apoptosis, at least during the later stages of activation ("activation-induced cell death") [7] [8] [9] .
Conflicting results have been obtained on the effects of expressing FasL in experimental solid organ allografts. For pancreatic islet cell allografts, the initial report found increased graft acceptance 10 , but later studies indicated that FasL + pancreatic allografts became infiltrated with neutrophils and suffered enhanced rejection 11 . Tolerance to FasL + allografts was shown in thyroid 12 and lung 13 models. FasL expression was also shown to inhibit allogeneic recognition of tumor cells 14 . The circumstances leading to these conflicting results are complex, and there are multiple differences among these model systems, including the strains of mice and the immunosuppressive regimens. In addition, the local environment may influence the nature of the response to FasL expression. For example, TGF-inhibited the proinflammatory effects of FasL in a tumor rejection model 15 .
In this initial investigation of this approach, we sought to determine whether allogeneic hematopoietic grafts might be protected from acute rejection, early after non- 
Methods

Viral vector construction and production.
The FasL gene expression vector was created by fusion of the mouse FasL coding region to the 5' end of the enhanced green fluorescent protein (GFP) gene, and subsequent insertion into a lentivirus vector under the control of the CMV-actin fusion promoter.
The control vector expresses only GFP. The lentivirus packaging system 16 and the selfinactivating lentiviral parent vector pRLL.hPGK.GFP SIn-18 17 have been described previously. The PGK promoter was removed from the parent vector, and additional 
Listeria monocytogenes challenge.
BALB/c mice, known to be susceptible to Listeria from preliminary studies, were lethally irradiated (850 cGy) and transplanted with syngeneic BALB/c lin -BMs that had been transduced with either the control GFP, or the FasL-GFP lentiviral vector. Three weeks later, transplanted mice were tail bled to quantify GFP + cells, then injected intraperitoneally (ip) with 10 6 colony-forming units (cfu) attenuated Listeria monocytogenes bacteria 22 . Four days after challenge, mice were sacrificed. Livers and spleens were removed, and portions were fixed in paraformaldehyde and analyzed histologically. The remainders of these organs were crushed to obtain single cell suspensions that were stained with CD8 Cy-chrome and either CD3-PE or CD4-PE monoclonal antibodies (BD-Pharmingen), then analyzed by FACS.
Results
Transduced lin -BMs were analyzed for expression of the transgene by (1) determination of GFP fluorescence (which should be present in both control vector-and experimental vector-transduced groups, since the experimental lentivirus encodes FasL as a GFPfusion) and (2) Untransduced DCs or DCs transduced with the FasL(-GFP fusion) or the control GFP vector were irradiated and incubated with responder spleen cells. In the allogeneic mixture (B6 DCs and BALB/c splenocyte responders), the control GFP + DCs stimulated a robust proliferative response, while the FasL + DCs failed to stimulate a response above background (Fig 1b) . 2C mice are transgenic for a CD8 + T cell receptor that recognizes H2 L d (displayed on BALB/c cells) [18] . Proliferation of 2C cells in response to BALB/c stimulators was essentially eliminated with the FasL + DCs.
Fig 1b
To begin to address the question of the specificity of the effects of FasL + DCs, we tested whether proliferation of responder T cells would be "non-specifically" inhibited by FasL 
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Three weeks after BMT, mice were tail-bled to determine the percentage of circulating cells that expressed the transgene (Fig 2d) . Both groups had similar percentages of GFP + cells, which were also similar to the percent GFP + input cells (Fig 2c) . only.
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Approximately three weeks later, mice were sacrificed and analyzed for donor cell hematopoietic engraftment. Donor cells and transduced cells were analyzed by correlated CD45.1 and GFP fluorescence. only.
Fig 3c
Representative histogram analyses for GFP from BM from transplanted mice, as labeled.
Fig 3d
BM cells from the allo-transplanted mice sacrificed at 3 weeks post-BMT (Table 1) were assessed for CFCs. No significant differences were observed in numbers or types of CFCs from the FasL-versus control GFP-transduced groups of mice (Figure 4 ). (Fig 5a, b) . Mild hepatic inflammation was noted in both groups but there was no difference in the levels of hepatic inflammation between the two groups. In the groups followed for 4-6 months, inflammation persisted to varying degrees in the transplanted mice; one of four FasL mice that were analyzed had detectably worse inflammation. only.
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To assess the immune responsiveness of allo-transplanted mice, splenocytes were taken at the time of sacrifice and used as responders in an MLR to a third party antigen stimulator (BALB/c, H-2 d ). No significant difference was observed between the two groups in the level of proliferation. (Fig 5c) .
Fig 5c
To further evaluate hepatotoxicity and to test the immune responsiveness of the transplanted mice, we challenged transplanted mice with a sublethal dose of Listeria monocytogenes as a model infectious agent. Listeria was selected since it is known to produce hepatic inflammation, and thus any inflammatory or hepatic in vivo toxicity of For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Listeria injection. On pathology, all mice had mild inflammation in the liver, with no gross differences between the two groups (Fig 6a) . All mice had high numbers of T cells in the livers in response to this challenge (Fig 6b) .
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Discussion
Results of this study suggest that HVG rejection was inhibited at time points early after transplant when FasL was genetically expressed in a fraction of the transplanted donor marrow cells. Increased levels of donor cells were detected in the host early after nonmyeloablative BMT, and no significant toxicity to the recipient mice was detected.
These results may serve as a paradigm for developing systems in which immune modulatory genes may be inserted into donor lin -BMs prior to BMT in order to engineer the recipient's immune response after BMT. Insertion of immunomodulatory genes into BM prior to transplant has the potential to be applied to diseases for which BMT is already utilized, to enhance the transplant effects, or to develop new therapies in which transplant could be employed for the purpose of introducing such genes. Thus, the capacity to modify immune responses through BMT would provide a significant potential for improvement of therapies for a number of diseases. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From myeloablative approaches. The goal of the present studies was to determine effects on acute allograft rejection. In addition, these studies do not address the potential for long term non-specific toxicity, e.g., late GVHD or late non-specific immunosuppression.
However, it appears that the FasL expression provides bystander protection and that not all the cells need to express FasL. In these experiments, clonal expansion of For 31 . In addition, we have recently found that CD34 + cells are resistant to Fasmediated cytotoxicity, and express low levels of Fas and high levels of FLIP. 25 However, since the detailed long-term effects of in vivo administered transduced FasL + BM cells are not fully known, this significant concern must be investigated. In these studies, the mice transplanted with FasL + lin -BMs appeared as healthy as the controls. No significant difference was observed in BM cellularity or CFC of mice transplanted with FasL + versus control lin -BMs. Since FasL has been shown to produce acute hepatotoxicity in some systems, we analyzed livers from transplanted mice histologically. Although there was minimal inflammation in both experimental and control mice (mild inflammation might be expected after a BMT), no difference was noted between the groups.
An evaluation of immune function of transplanted mice was conducted in two separate ways. First, spleen cells from the transplanted mice were used as responders in an MLR at the time of sacrifice, as a general determinant of intact immune responsiveness to an alloantigen. Mice that were transplanted with FasL + lin -BMs had no decrease in the ability to respond to allogeneic third party stimulation. Second, mice were evaluated for their ability to respond to an infectious agent (Listeria monocytogenes) at a dose that was determined empirically to produce severe but sublethal toxicity (A. Jain, R. Schulick, D.
Pardoll, unpublished observations). Mice that were significantly immunocompromised would be unable to mount an immune response to the agent and succumb. At 1-4 days after injection of the Listeria, all mice were alive but lethargic. At this time, they were sacrificed, and livers were analyzed by FACS for T cell infiltration and by histology.
Since each liver had a significant T cell infiltrate, the ability to mobilize T cells in response to an infectious antigen appeared to be intact in all mice.
These studies provide a novel approach to down-regulate graft rejection in BMT. Since
FasL has the potential to kill multiple cell types and to produce organ toxicity, Table 1: 10 5 transduced lin -BMs were transplanted iv into 400cGy irradiated C3H.SW (CD45.2 + ) recipients. Upon sacrifice at 3 weeks post-BMT, mouse organs were analyzed by FACS for correlated expression of CD45.1 and GFP. The graph shows the compilation of data for all mice shown in Table 1 , with the average percentage of CD45.1 + cells in BM of each group. Table 1 shows the data for each mouse analyzed, with the first column being the percent donor cells for mice receiving unmodified lin-BM, the second column being the percent donor cells for mice receiving GFP modified BM, the third showing percent donor cells from the FasL modified BM, and the fourth being the percent donor cells in the FasL transplants that were also GFP + .
Fig 3c: The figure shows a representative plot for CD45.1 for a mouse that was transplanted with GFP modified cells (top) and a mouse transplanted with FasL modified cells (bottom). Upon sacrifice of the mice described in Figure 3 , whole BM (3x10 5 cells) was assayed for CFC (triplicates). Seven days after plating, colonies were counted (averages +/-SEM are shown). Table 2 . Retention of graft at 4-6 months after transplant. Table 2 shows the percent donor chimerism of mice that were transplanted with modified cells and analyzed 4-6 months later. Four of 7 transplanted FasL mice retained the graft at detectable levels, while 0/7 GFP transplants retained the graft. No GFP positive cells were detected in the FasL transplants at this later timepoint. 
